Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 10/24 10:00:00 pm
2.27 USD   -0.44%
10/14 IMMUNOGEN, INC. : Announces Conference Call to Discuss its Financial..
09/29 IMMUNOGEN : Completes Strategic Review to Strengthen the Organizatio..
08/09 IMMUNOGEN : Announces Departure of Chief Development Officer
News SummaryMost relevantAll newsSector news 

ImmunoGen, Inc. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound

share with twitter share with LinkedIn share with facebook
share via e-mail
04/17/2012 | 12:20pm CEST

- First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 -

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate. The Phase I trial initiated evaluates the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in patients with non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials.

Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing.1 Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves: (1) to kill the cancer cells through multiple antibody-mediated mechanisms; and (2) to deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The Phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," commented James O'Leary, MD, Vice President and Chief Medical Officer. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

About the Phase I Trial Initiated

This multi-center, first-in-human Phase I trial is expected to enroll approximately 55 patients with relapsed or relapsed/refractory, CD37-expressing NHL. Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma - the more common types of NHL - are eligible for enrollment.

About IMGN529

ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target. The prevalence of CD37 on malignant cells is similar to that of CD20, the target for rituximab: it is expressed widely on key NHL subtypes - including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma and mantle cell lymphoma - and also on chronic lymphocytic leukemia (CLL).1

IMGN529 contains a CD37-targeting ImmunoGen antibody that, in vitro, has been found to kill cancer cells through multiple mechanisms of action including pro-apoptotic activity, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).1,2 The attached DM1 kills cancer cells through a different mechanism - disruption of a key step that occurs during cell division.

About Non-Hodgkin's lymphoma

NHL comprises a diverse group of cancers that all derive from defects in cellular production of lymphocytes, a type of white blood cell. As the name suggests, NHL includes all lymphomas except Hodgkin's lymphoma. Approximately 85% of cases of NHL are B-cell lymphomas. It is estimated that, in the US, approximately 56,000 people are diagnosed with B-cell NHL each year and 16,000 die from the disease.3

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

1Mayo M. et al., AACR 2011, abstract #4581.
2Deckert J. et al., AACR 2011, abstract #4565.
3American Cancer Society, What is non-Hodgkin's Lymphoma.

Rituxan® is a registered trademark of Biogen Idec Inc.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
For Media:
The Yates Network
Kathryn Morris, 845-635-9828

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on IMMUNOGEN, INC.
10/14 IMMUNOGEN, INC. : Announces Conference Call to Discuss its Financial Results for..
09/29 IMMUNOGEN INC : Costs Associated with Exit or Disposal Activities, Change in Dir..
09/29 IMMUNOGEN : Completes Strategic Review to Strengthen the Organization and Drive ..
09/16 IMMUNOGEN INC : Change in Directors or Principal Officers (form 8-K)
09/15 IMMUNOGEN : New Oligopeptides Study Findings Recently Were Reported by Researche..
09/09 IMMUNOGEN : Patent Issued for Preparation of Maytansinoid Antibody Conjugates by..
08/25 IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Resu..
08/25 IMMUNOGEN INC : Results of Operations and Financial Condition (form 8-K)
08/17 IMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements ..
08/09 IMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements ..
More news
Sector news : Biotechnology & Medical Research - NEC
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/29 ImmunoGen to cut 17% of workforce after strategic review; shares off 4% after..
09/29 AML THERAPIES PART 2 : Agios And ImmunoGen
08/24 Best And Worst Performing Stocks Of 2016
08/04 ImmunoGen's (IMGN) CEO Dan Junius on Q4 2016 Results - Earnings Call Transcri..
08/04 ImmunoGen, Inc. 2016 Q2 - Results - Earnings Call Slides
Financials ($)
Sales 2017 75,7 M
EBIT 2017 -119 M
Net income 2017 -146 M
Debt 2017 133 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 4,38x
EV / Sales 2018 4,20x
Capitalization 198 M
More Financials
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 5,71 $
Spread / Average Target 152%
Consensus details
EPS Revisions
More Estimates Revisions
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Joseph J. Villafranca Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.-83.27%198
CELLTRION, INC.--.--%10 691
LONZA GROUP AG13.37%9 614
ALKERMES PLC-28.58%8 592
More Results